352 related articles for article (PubMed ID: 26239299)
1. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
3. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
5. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
6. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
8. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
9. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.
Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M
J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
11. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.
Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028
[TBL] [Abstract][Full Text] [Related]
12. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
[No Abstract] [Full Text] [Related]
13. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.
Zhong M; Tian W; Zhuge J; Zheng X; Huang T; Cai D; Zhang D; Yang XJ; Argani P; Fallon JT; Epstein JI
Am J Surg Pathol; 2015 Jan; 39(1):127-31. PubMed ID: 25118812
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
[TBL] [Abstract][Full Text] [Related]
17. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
Günes C; Wezel F; Southgate J; Bolenz C
Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
[TBL] [Abstract][Full Text] [Related]
19.
Liu T; Li S; Xia C; Xu D
Front Immunol; 2022; 13():1071390. PubMed ID: 36713366
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
